BMS pays $10m up front to tap Santaris LNA platform
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb has entered into a worldwide strategic alliance with Santaris Pharma of Hoersholm, Denmark and San Diego to discover and develop medicines using Santaris' Locked Nucleic Acid (LNA) platform.